Dr. Reddy's Laboratories announces the launch of Treprostinil Injection in the U.S.

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced the launch of Treprostinil Injection in the U.S. market, a therapeutic equivalent generic version of Remodulin® (treprostinil) Injection, approved by U. S. Food and Drug Administration (USFDA).

Dr. Reddy's Treprostinil Injection is supplied as 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL or 200 mg/20 mL vials.

Shares of Dr. Reddy's Laboratories Limited was last trading in BSE at Rs. 4858.05 as compared to the previous close of Rs. 4908.95. The total number of shares traded during the day was 24808 in over 9578 trades.

The stock hit an intraday high of Rs. 4913.40 and intraday low of 4820.60. The net turnover during the day was Rs. 120593705.00.

Source : Equity Bulls

Keywords

DrReddysLaboratories INE089A01023 RDY TreprostinilInjection USFDA USMarket